JAK2 V617F基因突变与血管栓塞性疾病的相关性研究  

Relationship between JAK2 V617F gene mutation and vascular embolism diseases

作　　者：张维[1] 刘艳[1] 万岁桂[1] 赵弘[1] 孙婉玲[1] 田丁[1] 

机构地区：[1]首都医科大学宣武医院血液科,北京100053

出　　处：《白血病．淋巴瘤》2015年第7期431-432,共2页Journal of Leukemia & Lymphoma

摘　　要：目的 探讨JAK2 V617F基因突变与血管栓塞性疾病的相关性,为临床诊治和预防栓塞提供依据.方法 以首都医科大学宣武医院神经内科、心脏科及血管外科收治的血红蛋白＞ 160g/L、血小板计数＞ 300×109/L的56例患者为研究对象,其中骨髓增殖性肿瘤患者47例.回顾性分析患者血管栓塞情况、JAK2 V617F突变情况及两者之间的相关性.结果 JAK2 V617F基因突变阳性率为37.50％（21/56）,血管栓塞发生率为41.07％（23/56）,两者之间存在关联性（P=0.014）.结论 JAK2 V617F基因突变检测有助于骨髓增殖性肿瘤患者的早期诊断和治疗,减少栓塞并发症,提高患者生命质量.Objective To investigate the relationship between JAK2 V617F mutation and vascular embolism diseases,in order to provide important basis for clinical diagnosis and treatment and prevention of embolism.Methods Patients who were hemoglobin 〉 160 g/L,platelets 〉 300×109/L treated in department of neurology,heart and vascular surgery in Xuanwu Hospital of Capital Medical University were collected.Vessel embolism and JAK2 V617F mutation situation and correlation were retrospectively analyzed.Results Among the total 56 cases,JAK2 V617F gene mutation positive rate was 37.50 % （21/56）,the incidence of embolism was 40.07 % （23/56）,there was correlation between JAK2 V617F mutation and embolism （P =0.014）.Conclusion JAK2 V617F mutation is helpful to early diagnosis and treatment of myeloproliferative neoplasm,reduce thrombosis complication,improve the quality of life.

关 键 词：骨髓增殖性肿瘤 JAK2 V617F基因突变 栓塞 

分 类 号：R733.3[医药卫生—肿瘤]